News|Articles|October 31, 2024
WCG Meets Enrollment 24 Months Early for Top 5 Pharma’s Decentralized Trial
Author(s)WCG Clinical
A sponsor needed to get their Phase II dermatology study enrollment back on track. The study was underway for 11 months across 32 sites globally with only 20 subjects enrolled to date. With WCG support, enrollment was concluded 24 months ahead of schedule.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
Gilead’s ARTISTRY-2 Trial Shows Bictegravir Lenacapavir Combo Matches Biktarvy in Virologically Suppressed Adults With HIV
2
Preparing for End-to-End AI-Enabled Clinical Trials
3
ACT Brief: AI-Enabled End-to-End Trials, New Phase III Data in HIV, and a First-Line Shift in HER2-Positive Breast Cancer
4
What Patients Want from Remote Trials: New Survey Data Reveals Preferences Around Usability, Trust, and Participation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
